The estimated Net Worth of Alan S. Roemer is at least $16.9 Tisíc dollars as of 16 August 2022. Alan Roemer owns over 26,315 units of In8 Bio stock worth over $16,942 and over the last 3 years Alan sold INAB stock worth over $0.
Sign up
Alan Roemer INAB stock SEC Form 4 insiders trading
Alan has made over 1 trades of the In8 Bio stock since 2022, according to the Form 4 filled with the SEC. Most recently Alan bought 26,315 units of INAB stock worth $49,999 on 16 August 2022.
The largest trade Alan's ever made was buying 26,315 units of In8 Bio stock on 16 August 2022 worth over $49,999. On average, Alan trades about 3,759 units every 0 days since 2021. As of 16 August 2022 Alan still owns at least 55,989 units of In8 Bio stock.
You can see the complete history of Alan Roemer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Alan Roemer's mailing address?
Alan's mailing address filed with the SEC is C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK, NY, 10118.
Insiders trading at In8 Bio
Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L... a Emily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.
What does In8 Bio do?
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does In8 Bio's logo look like?
Complete history of Alan Roemer stock trades at In8 Bio
In8 Bio executives and stock owners
In8 Bio executives and other stock owners filed with the SEC include:
-
William Ho,
Co-Founder, Pres, CEO & Director -
Dr. Lawrence S. Lamb Ph.D.,
Exec. VP, Co-Founder & Chief Scientific Officer -
Dr. Trishna Goswami M.D.,
Chief Medical Officer -
Charles Butler,
VP of Investor Relations & Communications -
Dr. Kate Rochlin Ph.D.,
Chief Operating Officer -
Patrick McCall CPA,
Chief Financial Officer -
Emily Fairbairn,
-
Travis Whitfill,
-
Jeremy R. Graff,
-
Luba Greenwood,
-
Alan S. Roemer,
-
Corinne Epperly,
-
Lawrence Lamb,
EVP and CSO -
Leslie W.Bios Equity Partne...,
-
Aaron G.L.Bios Fund Ii, Lpb...,
-
Peter C. Brandt,
-
William Tai Wei Ho,
PRESIDENT AND CEO -
Aaron G.L.Bios Fund Iii, Lp...,
-
Emily Transcend Partners Op...,
-
Leslie W.Bios Fund Ii Nt, L...,
-
Leslie W.Cavu Management, L...,
-
Aaron G.L.Bios Capital Mana...,
-
Leslie W.Bios Fund Ii Nt, L...,
-
Aaron G.L.Bios Equity Partn...,
-
Aaron G.L.Bios Fund Ii Nt, ...,
-
Leslie W.Bios Equity Partne...,
-
Kate Rochlin,
Chief Operating Officer -
Patrick Mc Call,
CHIEF FINANCIAL OFFICER -
Trishna Goswami,
Chief Medical Officer